Clinical Research Directory

Inclusion Criteria: * Participants voluntarily agree to participate in the study and provide written informed consent. * Age ≥18 years at the time of signing the informed consent form. * Histologically confirmed recurrent or metastatic cervical cancer (FIGO 2018 stage IVB), including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. * Disease progression or treatment failure following prior platinum-based chemotherapy. * At least one measurable target lesion according to RECIST version 1.1, as assessed by CT or MRI. * Estimated life expectancy of at least 3 months. * Considered suitable by the investigator for antitumor treatment with Iparomlimab and Tuvonralimab (QL1706), either as monotherapy or in combination with other therapies, and with a planned treatment regimen including QL1706. Exclusion Criteria: * Histological subtypes including sarcoma, small-cell carcinoma with neuroendocrine differentiation, or other non-epithelial malignancies. * History of severe hypersensitivity reaction (Grade ≥3) to Iparomlimab and Tuvonralimab (QL1706) and/or any of its excipients. * Known additional malignancy that has progressed or required active treatment within the past 3 years. * Active autoimmune disease requiring systemic treatment within the past 2 years (e.g., disease-modifying agents, corticosteroids, or immunosuppressive therapy); history of non-infectious pneumonitis requiring steroid treatment, or current pneumonitis. * Active infection requiring systemic therapy. * Any other medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would make the participant unsuitable for participation in this study.